Advertisement

Research Article Free access | 10.1172/JCI117427

Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.

M A Hussain, O Schmitz, A Mengel, Y Glatz, J S Christiansen, J Zapf, and E R Froesch

Department of Internal Medicine, University Hospital of Zürich, Switzerland.

Find articles by Hussain, M. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University Hospital of Zürich, Switzerland.

Find articles by Schmitz, O. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University Hospital of Zürich, Switzerland.

Find articles by Mengel, A. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University Hospital of Zürich, Switzerland.

Find articles by Glatz, Y. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University Hospital of Zürich, Switzerland.

Find articles by Christiansen, J. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University Hospital of Zürich, Switzerland.

Find articles by Zapf, J. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University Hospital of Zürich, Switzerland.

Find articles by Froesch, E. in: JCI | PubMed | Google Scholar

Published September 1, 1994 - More info

Published in Volume 94, Issue 3 on September 1, 1994
J Clin Invest. 1994;94(3):1126–1133. https://doi.org/10.1172/JCI117427.
© 1994 The American Society for Clinical Investigation
Published September 1, 1994 - Version history
View PDF
Abstract

Insulin-like growth factor-I (IGF-I) is considered to be the mediator of the growth-promoting effects of growth hormone (GH). The metabolic effects of these two hormones, however, are different. Whereas GH treatment leads to elevated insulin and glucose levels, reduced insulin sensitivity, and impaired glucose tolerance, IGF-I treatment leads to reduced insulin and GH levels and enhanced insulin sensitivity. IGF-I may, therefore, not only be the mediator of the growth-promoting effects of GH but also a modulator of the effects of GH on insulin action and glucose metabolism. To study the influence of GH and IGF-I on substrate metabolism and insulin sensitivity (assessed by euglycemic, hyperinsulinemic clamping combined with indirect calorimetry and glucose tracer infusion), we have treated eight GH-deficient adults with GH (2 IU/m2 daily subcutaneously [s.c.]), IGF-I (10 micrograms/kg.h s.c.), or both hormones together for 7 d, respectively, and compared the effects of these treatment regimens with a control phase. Our findings suggest that (a) both GH and IGF-I promote lipolysis and lipid oxidation, albeit by different mechanisms; (b) treatment with either hormone is followed by enhanced energy expenditure and reduced protein oxidation; and (c) IGF-I reverses the insulin resistance induced by GH.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (September 1, 1994): No description
Advertisement
Advertisement